Global Collaboration to Tackle Psoriasis: A Turning Point for Millions
A landmark agreement between the International Federation of Psoriasis Associations (IFPA) and the WHO Foundation signals a new era in the global fight against psoriasis. Signed on February 10, 2026, this multi-year collaboration aims to dramatically improve the lives of the over 100 million people worldwide living with this chronic condition.
Beyond the Skin: Understanding the Systemic Impact of Psoriasis
Psoriasis is often perceived as a skin condition, but its impact extends far beyond the surface. It’s closely linked to serious health issues like depression, diabetes, obesity, and cardiovascular disease. This systemic nature of the disease underscores the demand for a holistic approach to care.
The Data Gap: Why Accurate Epidemiology Matters
A significant challenge in addressing psoriasis globally is the lack of reliable data. Currently, only around 20 percent of countries have epidemiological data on psoriasis, according to the Global Psoriasis Atlas. This absence hinders early diagnosis, equitable access to care, and a comprehensive understanding of the disease’s impact on individuals and healthcare systems.
Key Focus Areas of the IFPA-WHO Collaboration
The collaboration will concentrate on several crucial areas:
- Strengthening Evidence: Gathering and analyzing data to better understand the prevalence, impact, and effective treatments for psoriasis.
- Updating Knowledge and Policy Tools: Developing and disseminating evidence-based guidelines for diagnosis, management, and care.
- Improving Access to Diagnosis and Care: Expanding access to affordable and effective treatments, particularly in low- and middle-income countries.
- Revising the Global Report on Psoriasis: Updating the landmark 2016 report with new prevalence data, scientific advances, and treatment developments.
- AI-Driven Diagnostics: Developing artificial intelligence tools for earlier and more accurate detection, especially in resource-limited settings.
- Healthcare Professional Training: Equipping healthcare providers with the knowledge and skills to effectively recognize and manage psoriasis.
Addressing Stigma and Discrimination
The collaboration recognizes the significant social and emotional burden of psoriasis. More than 80% of people with psoriasis face stigma and discrimination, nearly half struggle with anxiety, and a third report avoiding career or study opportunities due to their condition. Efforts will be made to raise awareness and combat these issues.
Leveraging Past Successes
This new initiative builds upon the foundation laid by the 2014 resolution on psoriasis and the 2016 Global Report on Psoriasis, which brought the condition onto the global health agenda for the first time. Updating these key documents is a critical step in sustaining momentum and driving further progress.
The Role of the WHO Foundation and IFPA
The WHO Foundation will leverage its global health leadership and fundraising capabilities to mobilize support for WHO-led efforts. The IFPA, with its extensive network of patient organizations representing over 60 million people, will provide crucial patient perspectives and advocacy.
Future Trends: Integrating Psoriasis into Broader Health Initiatives
This collaboration is expected to integrate psoriasis into broader global conversations about chronic diseases and mental health, ensuring that those affected are no longer overlooked. The development of AI-driven diagnostic tools promises to revolutionize early detection, particularly in areas with limited access to specialized healthcare.
Frequently Asked Questions
What is the main goal of the IFPA-WHO collaboration?
To strengthen global understanding, diagnosis, and care for psoriasis, ultimately improving the lives of the over 100 million people affected worldwide.
Why is data collection so key?
Accurate epidemiological data is crucial for early diagnosis, equitable access to care, and a comprehensive understanding of the disease’s impact.
How will this collaboration address stigma?
By raising awareness and advocating for policies that combat discrimination against people living with psoriasis.
What is the role of AI in this initiative?
AI will be used to develop diagnostic tools for earlier and more accurate detection, especially in low-resource settings.
Where can I learn more about the IFPA?
Visit https://www.ifpa-pso.com/
Where can I learn more about the WHO Foundation?
Visit https://www.who.foundation/
What can you do to assist? Share this article with your network to raise awareness about psoriasis and the importance of global collaboration. Support organizations like the IFPA and the WHO Foundation in their efforts to improve the lives of those affected by this chronic condition.
